Centre de Recherches en Cancérologie de Toulouse, UMR 1037, Toulouse, F-31037, France.
INSERM, UMR 1037, Université Toulouse III Paul Sabatier, Toulouse, F-31062, France.
Med Phys. 2020 Sep;47(9):4602-4615. doi: 10.1002/mp.14375. Epub 2020 Jul 31.
The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE (LUTATHERA ).
The dosimetric analysis was performed on two patients during two cycles of PRRT with Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit (DTK) from Xeleris™ and HybridRecon-Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time-integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations.
The majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms.
When applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms.
本研究旨在通过分析接受 Lu-DOTATATE(LUTATHERA)肽受体放射性核素治疗(PRRT)的患者的临床数据集,对五种商业剂量学软件平台进行定量比较。
对两名患者在两次 Lu 进行 PRRT 治疗期间进行了剂量分析。在注射后 4、24、72 和 192 小时采集单光子发射计算机断层扫描/计算机断层扫描图像。使用 Xeleris™中的 Dosimetry Toolkit(DTK)和 HERMES 中的 HybridRecon-Oncology version_1.3_Dicom(HROD)生成重建图像。使用相同的软件分析使用 DTK 重建的图像,以计算时间积分活度系数(TIAC),并使用 OLINDA/EXM V1.0 进行质量校正后估计平均吸收剂量。将来自 HROD 的重建图像上传到 DOSIsoft 的 PLANET®OncoDose、Phillips 的 STRATOS、HERMES 的 Hybrid Dosimetry Module™和 MIM 的 SurePlan™MRT。使用各自的推荐方法从每个应用程序中计算器官质量、TIAC 和平均吸收剂量。
大多数器官质量估计值在所有平台之间的差异<9.5%。在两名患者和两个治疗周期中,平台之间 TIAC 结果的最大差异见于肾脏(28.2%)。与 TIAC 观察到的结果相比,平均吸收剂量的相对标准偏差略高,但在所有平台之间仍处于同一数量级。
当应用相似的处理方法时,无论使用的平台如何,结果都处于同一数量级。然而,由于目前可用的平台并非都涉及剂量分析工作流程的相同部分,因此仍然难以比较它们的性能。此外,从数据采集到吸收剂量的每个链部分处理数据的方式可能不同,这使得比较变得复杂。因此,吸收剂量计算的商业解决方案的传播需要开发允许在剂量学软件平台之间比较性能的工具和标准。